Page last updated: 2024-08-23

sq-11725 and Alzheimer Disease

sq-11725 has been researched along with Alzheimer Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cain, DP; Saber, AJ	1

Other Studies

1 other study(ies) available for sq-11725 and Alzheimer Disease

Article	Year
Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:7 Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Male; Maze Learning; Muscarinic Antagonists; Nadolol; Propranolol; Psychomotor Performance; Rats; Rats, Long-Evans; Scopolamine; Spatial Behavior; Time Factors	2003

Article

Year

Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:7

Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Male; Maze Learning; Muscarinic Antagonists; Nadolol; Propranolol; Psychomotor Performance; Rats; Rats, Long-Evans; Scopolamine; Spatial Behavior; Time Factors

2003